small molecule

ORUVAIL

KETOPROFEN

Loss of exclusivity—loss of exclusivity

CompanyWyeth →See this company's full patent-cliff portfolio

Drug detail

Brand name	ORUVAIL
Active ingredient	KETOPROFEN
Strength	150MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons
Dosage form	CAPSULE, EXTENDED RELEASE
Route	ORAL
Modality	Small molecule
FDA approval	February 1995
Marketing status	DISCN

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.